Perjeta – A potential drug for HER-positive breast cancer

28 June 2012, USA( As per some recent data from the Genetech pharmaceutical company, shows that its drug Perjeta, when used in conjugation with other breast cancer drugs posses the potential to lower the risk of metastatic breast cancer in individuals suffering from HER2-positive type of cancer. The therapeutic approach used in conjugation with Perjeta (Pertuzumab) are Herceptin (trastuzumab) and docetaxel chemotherapy and proved that this measure significantly lowered the risk of people with HER2-positive metastatic breast cancer as compared to the use of chemotherapy of docetaxel and Herceptin alone in its phase III clinical trials known as CLEOPATRA (CLinical Evaluation Of Pertuzumab And TRAstuzumab) study. The progression free survival (PFS) that was assessed by an independent committee was considered as the primary endpoint of the clinical study. Whereas, overall survival, overall response rate (ORR), extent of time and response associated with progression of symptoms as well as its safety profile, formed the secondary endpoints of the study. Hal Barron, chief medical officer of the Global Product Development said that they are very happy and contented with the results obtained through the CLEOPATRA study and the fact that Perjeta greatly aids people afflicted with HER2-positive metastatic breast cancer to lead a longer life by hindering the progression of the disease is really a great news for all those individuals suffering from the clinical condition. He also added that the current clinical study may change the overall perspective of doctor’s as well as patients afflicted with this detrimental health condition. FDA has also approved the use of Perjeta in conjugation with docetaxel and Herceptin chemotherapy. Perjeta targets the HER2 receptors present on the HER2-positive cancer cells and acts in a complementary manner to that of Herceptin, although the target receptors of both of them are different. The side effects of this therapeutic approach range from less severe and common to severe adverse health impacts. For more: 4th lane, 278 Stockton, California states, USA